Plain-English translation of NCT07333716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Ulcerative colitis is a long-lasting inflammation of the colon that can be hard to treat. This trial is testing whether — a medication commonly used for allergies — might help reduce inflammation when added to the standard treatment (). Early laboratory work suggests this medication may calm the immune response and reduce harmful chemicals that drive inflammation.
Standard treatments don't work well enough for everyone with ulcerative colitis, especially in regions like Egypt where the disease is becoming more common. Researchers discovered in lab studies that this medication has anti-inflammatory properties that might ease symptoms, so they want to test whether it actually helps real patients.
You likely qualify if…
You likely don't qualify if…
You will be in the study for 3 months. Half of participants will take the standard treatment alone, while the other half will take plus the new medication () once daily. You'll take your medications at home and likely visit the clinic for check-ups to see how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Egypt
Testing effectiveness
Sponsor
Tanta University
Enrollment target
~44 participants
Started
January 2026
Primary completion
February 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Romisaa R Abd Alnapy
Tanta University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.